Clinical Trials Logo

Lymphoma, Diffuse Large-Cell clinical trials

View clinical trials related to Lymphoma, Diffuse Large-Cell.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT01415765 Withdrawn - Clinical trials for Diffuse, Large B-cell Lymphoma

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Start date: July 15, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Background: - MLN4924 is an experimental cancer drug. It may help kill lymphoma cells and make them more sensitive to chemotherapy. EPOCH R is a combination chemotherapy drug. It has been effective in treating some cases of large B-cell lymphoma. This research will look at two things. The first is the effect of MLN4924 on its own in treating large B-cell lymphoma. The second is the safe dose and effect of MLN4924 and EPOCH-R in combination when treating large B-cell lymphoma. Objectives: - To study how MLN4924 affects large B-cell lymphoma tumors. - To compare the effects of MLN 4924 alone and MLN4924 plus standard EPOCH-R chemotherapy. Eligibility: - Individuals at least 18 years of age who have large B-cell lymphoma that will be treated with chemotherapy. Design: - Participants will be screened with a medical history and physical exam. They will also have blood and urine tests, tumor samples, and imaging studies. - Participants will receive MLN4924 for a maximum of six 21-day cycles of treatment. Each cycle involves a dose of MLN4924 twice a week for 2 weeks, followed by a 1-week rest period. Participants will be monitored with frequent blood tests and imaging studies. - Participants who do not benefit from MLN4924 alone will have MLN4924 along with EPOCH-R chemotherapy for up to six cycles of treatment.